- Home
- ALDF vs TSHA Comparison
ALDF vs TSHA Comparison
Compare ALDF & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDF
- TSHA
- Stock Information
- Founded
- ALDF 2024
- TSHA 2019
- Country
- ALDF United States
- TSHA United States
- Employees
- ALDF N/A
- TSHA N/A
- Industry
- ALDF
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- ALDF
- TSHA Health Care
- Exchange
- ALDF NYSE
- TSHA Nasdaq
- Market Cap
- ALDF 313.9M
- TSHA 728.4M
- IPO Year
- ALDF 2024
- TSHA 2020
- Fundamental
- Price
- ALDF $10.47
- TSHA $2.43
- Analyst Decision
- ALDF
- TSHA Strong Buy
- Analyst Count
- ALDF 0
- TSHA 5
- Target Price
- ALDF N/A
- TSHA $8.20
- AVG Volume (30 Days)
- ALDF 77.1K
- TSHA 3.5M
- Earning Date
- ALDF 01-01-0001
- TSHA 08-11-2025
- Dividend Yield
- ALDF N/A
- TSHA N/A
- EPS Growth
- ALDF N/A
- TSHA N/A
- EPS
- ALDF N/A
- TSHA N/A
- Revenue
- ALDF N/A
- TSHA $7,224,000.00
- Revenue This Year
- ALDF N/A
- TSHA N/A
- Revenue Next Year
- ALDF N/A
- TSHA N/A
- P/E Ratio
- ALDF $100.18
- TSHA N/A
- Revenue Growth
- ALDF N/A
- TSHA N/A
- 52 Week Low
- ALDF $9.90
- TSHA $1.05
- 52 Week High
- ALDF $10.69
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- ALDF N/A
- TSHA 47.43
- Support Level
- ALDF N/A
- TSHA $2.25
- Resistance Level
- ALDF N/A
- TSHA $2.48
- Average True Range (ATR)
- ALDF 0.00
- TSHA 0.16
- MACD
- ALDF 0.00
- TSHA -0.04
- Stochastic Oscillator
- ALDF 0.00
- TSHA 36.73
About ALDF ALDEL FINL II INC
Aldel Financial II Inc is a Shell Company with various businesses.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.